Evidence map›Paper›PMID 33442956›Full record

ArticleThoracic cancer2021

Coexistence of atypical adenomatous hyperplasia, minimally invasive adenocarcinoma and invasive adenocarcinoma: Gene mutation analysis.

Junya Song, Yinghui Xu, Zhiguang Yang, Yunpeng Liu, Peng Zhang, Xu Wang, Chao Sun, Ye Guo, Shi Qiu, Guoguang Shao and 1 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Thoracic cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. The Current Roadmap of Lung Cancer Biology, Genomics and Racial Disparity.International journal of molecular sciences · 2025
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 2 countries.

Junya Song *Cancer Center, The First Hospital of Jilin University, Changchun, China.ORCID 0000-0003-3329-8598
Yinghui Xu *Cancer Center, The First Hospital of Jilin University, Changchun, China.
Zhiguang Yang *Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China.
Yunpeng LiuThoracic Surgery Department, The First Hospital of Jilin University, Changchun, China.
Peng ZhangThoracic Surgery Department, The First Hospital of Jilin University, Changchun, China.
Xu WangCancer Center, The First Hospital of Jilin University, Changchun, China.
Chao SunCancer Center, The First Hospital of Jilin University, Changchun, China.
Ye GuoCancer Center, The First Hospital of Jilin University, Changchun, China.
Shi QiuCancer Center, The First Hospital of Jilin University, Changchun, China.
Guoguang ShaoThoracic Surgery Department, The First Hospital of Jilin University, Changchun, China.
Kewei MaCancer Center, The First Hospital of Jilin University, Changchun, China.ORCID 0000-0003-2987-576X
Jilin University · CN

Funding

Xisike Clinical Oncology Research Foundation (CSCO-Haosen) Y-HS2017-062Youth Foundation of The First Hospital of Jilin University JDYY82017020
6 · The paper itself

Abstract

Multiple primary lung cancer (MPLC) refers to the simultaneous occurrence of two or more lung primary malignant tumors in one individual. The detection rate of MPLC has increased significantly in recent years, and the distinction between MPLC and lung metastasis has strong clinical significance. Whole exome sequencing (WES) can clearly identify the heterogeneity between MPLC nodules. Here, we report a case of a 50-year-old Asian female without a history of smoking. She underwent a lung computed tomography (CT) scan and three ground-glass nodules (GGNs) were found which were pathologically confirmed as atypical adenomatous hyperplasia (AAH), minimally invasive adenocarcinoma (MIA) and invasive adenocarcinoma (IA), respectively. We performed WES on the three pulmonary nodules and analyzed the sequencing results. We believe that this is the first published report of a case of "three phases" of lung adenocarcinoma analyzed by WES. Under the same genetic background and internal environment, these three nodules showed significant genetic differences and developed into "three phases" of lung adenocarcinoma. Analysis of the WES results supported the lung adenocarcinoma model from AAH to MIA and IA, and explored possible potential driver genes and therapeutic targets. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: We used WES to analyze the gene mutation status of three tumors in one individual. We found that even if under the same genetic background, AAH, MIA and IA showed significant genetic differences and developed into "three phases" of lung adenocarcinoma. WHAT THIS STUDY ADDS: Analysis of the WES results supported the lung adenocarcinoma model from AAH to MIA and IA, and explored possible potential driver genes and therapeutic targets.

Indexed as

AdenocarcinomaFemaleHumansHyperplasiaMiddle AgedMutationMultiple primary lung cancer (MPLC)mutation spectrumphylogenetic treetumor mutation burden (TMB)whole exome sequencing (WES)

Identifiers

PMID33442956
PMCPMC7919134
OpenAlexW3119088194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.